CN105030684A - Formula for polyhexamethylene guanidine medicine powder and capsules and method for preparing same - Google Patents
Formula for polyhexamethylene guanidine medicine powder and capsules and method for preparing same Download PDFInfo
- Publication number
- CN105030684A CN105030684A CN201510428434.6A CN201510428434A CN105030684A CN 105030684 A CN105030684 A CN 105030684A CN 201510428434 A CN201510428434 A CN 201510428434A CN 105030684 A CN105030684 A CN 105030684A
- Authority
- CN
- China
- Prior art keywords
- polyhexamethylene guanidine
- capsules
- medicine powder
- formula
- polyhexamethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a formula for polyhexamethylene guanidine medicine powder and capsules and a method for preparing the same, and relates to the field of technologies for manufacturing medicine powder and capsules. The formula includes 0.5-10% of polyhexamethylene guanidine, 25-35% of anhydrous dextrose, 40-45% of lactose and 10-35% of corn starch. The method for preparing the polyhexamethylene guanidine medicine powder and capsules includes a first step, uniformly mixing and stirring the polyhexamethylene guanidine and the corn starch with each other for 30 minutes according to proportions to obtain mixtures A; a second step, uniformly mixing and stirring the mixtures A and the anhydrous dextrose with one another for 30 minutes according to the proportions to obtain mixtures B; a third step, uniformly mixing and stirring the mixtures B and the lactose with one another for 30 minutes according to the proportions to obtain the polyhexamethylene guanidine medicine powder; a fourth step, filling capsules with the polyhexamethylene guanidine medicine powder according to certain quantities to obtain the polyhexamethylene guanidine medicine capsules. The formula and the method have the advantages that the polyhexamethylene guanidine medicine powder and capsules and germs act with one another after the polyhexamethylene guanidine medicine powder and capsules enter the intestines and the stomachs of patients, the polyhexamethylene guanidine medicine powder and capsules can become effective fast and can be prevented from remaining in the bodies of the patients, and medicine resistance and side and toxic effects can be prevented.
Description
Technical field:
The present invention relates to drug powder and capsule manufacturing technology field, be specifically related to a kind of polyhexamethylene guanidine drug powder, the formula of capsule and preparation method.
Background technology:
The medicine of the diarrhoea that existing treatment is caused by antibacterial, viral infection, acute chronic gastroenteritis, superficial gastritis, gastric ulcer is the antibiotic such as sulfa drugs, quinolones, ciprofloxacin, ofloxacin, amoxicillin, gentamycin sulfate, these medicines enter blood and lymph fluid through digestive tube mucomembranous epithelial cell after being taken by human body, extensive distribution also residues in each tissue, not only lesions position is worked, and to human normal tissue toxic side effect.These medicines of life-time service, also can be able to develop immunity to drugs to each bacterioid, fungus, virus, and bactericidal effect is by the impact of antibacterial, fungus, virus variation.
Summary of the invention:
The object of this invention is to provide a kind of polyhexamethylene guanidine drug powder, the formula of capsule and preparation method, after it enters the intestines and stomach directly and pathogenic bacteria interact, rapid-action, and do not remain in vivo, can not develop immunity to drugs, have no side effect.
In order to solve the problem existing for background technology, the present invention adopts following technical scheme: its formula is: polyhexamethylene guanidine 0.5-10%, anhydrous glucose 25-35%, lactose 40-45%, corn starch 10-35%.
Its preparation technology is:
Step one: according to aforementioned proportion, mixes stirring 30 minutes by polyhexamethylene guanidine and corn starch, obtains mixture A;
Step 2: according to aforementioned proportion, mixes stirring 30 minutes by mixture A and anhydrous glucose, obtains mixture B;
Step 3: according to aforementioned proportion, mixes stirring 30 minutes by mixture B and lactose, obtains polyhexamethylene guanidine drug powder;
Step 4: by polyhexamethylene guanidine drug powder according in a certain amount of incapsulating, just obtain polyhexamethylene guanidine medicament capsule.
The present invention has following beneficial effect: after entering the intestines and stomach directly and pathogenic bacteria interact, rapid-action, and do not remain in vivo, can not develop immunity to drugs, have no side effect.
Detailed description of the invention:
This detailed description of the invention adopts following technical scheme: its formula is: polyhexamethylene guanidine 0.5-10%, anhydrous glucose 25-35%, lactose 40-45%, corn starch 10-35%.
Its preparation technology is:
Step one: according to aforementioned proportion, mixes stirring 30 minutes by polyhexamethylene guanidine and corn starch, obtains mixture A;
Step 2: according to aforementioned proportion, mixes stirring 30 minutes by mixture A and anhydrous glucose, obtains mixture B;
Step 3: according to aforementioned proportion, mixes stirring 30 minutes by mixture B and lactose, obtains polyhexamethylene guanidine drug powder;
Step 4: by polyhexamethylene guanidine drug powder according in a certain amount of incapsulating, just obtain polyhexamethylene guanidine medicament capsule.
This detailed description of the invention tool has the following advantages:
One, direct effect is rapid-action: directly interacts with pathogenic bacteria after entering the intestines and stomach, being attracted each other by positive and negative charge is wound around and wraps up pathogenic bacteria, and cut-out pathogenic bacteria nutrient absorption passage also suppresses it to divide, and pathogenic bacteria is choked to death.Other similar drugs are participate in cellular metabolism and upset or check metabolic pathway and reach sterilization object substantially.
Two, do not absorb and do not remain: effective ingredient is macromolecule polyalcohol, can not absorb by digested pipe mucomembranous epithelial cell, directly excreted with stool form by large intestine after this product enters the intestines and stomach.Other similar drugs then can enter blood and lymph fluid through digestive tube mucomembranous epithelial cell, extensively distribute and residue in each tissue, body fluid, as liver, kidney, lung, prostate, testis, uterus and bile, sputum, vesicle liquid, blood, urine etc.
Three, without Drug resistance: unique pathogenic bacteria principle (parcel pathogenic bacteria suppresses division to make it be choked to death) of killing makes it without Drug resistance, and long-term taking effect does not subtract.
Four, have no side effect: enter in human body not absorb and do not remain, directly excrete, to human non-toxic's side effect.
Five, Mucosa for Protective Effect: also have very strong covering protection ability to alimentary canal mucous membrane, repairs, improves Mucosa Barrier to the defense function of attack factor, has balance normal flora and local analgesic effect.
Pharmacology and metabolism: can with the cell membrane effect usually in elecrtonegativity antibacterial after entering digestive system, destroy microorganisms storage power and nutrient carry necessary ion gradient, even cause endochylema seepage.In this product, effective ingredient becomes electropositive simultaneously, be easy to by electronegative each bacterioid, virus adsorb and be wound around, thus suppress the splitting function of pathogenic bacteria, make antibacterial lose fertility, add the respiration channel plugging microorganism, microorganism is choked to death rapidly.The sterilization mechanism of its uniqueness, does not develop immunity to drugs to each bacterioid, fungus, virus, and bactericidal effect is not by the impact of antibacterial, fungus, virus variation.This product enters in human body and is not absorbed by human body cell, directly excretes after stomach, intestinal.
Antimicrobial spectrum: all have stronger killing action to enterovirus such as Coxsackie virus, echovirus, enterovirus EV 71 types.To gram-negative bacteria, comprise escherichia coli, pneumobacillus, Proteus, Bacillus typhi, Salmonella paratyphi, Shigella, enterobacter cloacae, clostridium perfringen, the acid of structure rafter Pseudomonas, Serratia marcesens, bacillus pyocyaneus, meningococcus, hemophilus influenza, mucositis mora bacterium, all have stronger bactericidal action addicted to lung cenobium bacterium, gonococcus etc., to the gram positive coccus such as staphylococcus, Streptococcus hemolyticus, also there is stronger killing action.
Toxicity: through repeatedly intact skin stimulation and a damaged skin experiment, belong to nonirritant; All belong to nontoxic through acute oral toxicity, acute inhalation toxicity, Skin Irritation Test, Eye irritation, subacute toxicity test, micronucleus test.Mice tested material this product acute oral toxicity test shows: female male mice LD50 is all greater than 25mg/kg.bw (calculating by active ingredient).Rat tested material this product dosage is 5mg/kg.bw (calculating by active ingredient), every day gavage once, continuous 28 days, testing result was: in peripheral blood cell counts, the indices such as hemoglobin, red blood cell count(RBC), numeration of leukocyte, lymphocyte, mononuclear cell is uninfluenced; In blood biochemistry checking, the index such as glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, blood urea nitrogen, liver acid anhydride, cholesterol, alkali phosphatase, glucose, total protein content is uninfluenced; Each internal organs (liver,kidney,spleen) weight coefficient is uninfluenced, and the heart, liver, lung, kidney, spleen, brain, intestines and stomach and testis/ovary etc. are showed no obvious naked eyes pathological changes.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (2)
1. a formula for polyhexamethylene guanidine drug powder, capsule, is characterized in that its formula is: polyhexamethylene guanidine 0.5-10%, anhydrous glucose 25-35%, lactose 40-45%, corn starch 10-35%.
2. a preparation method for polyhexamethylene guanidine drug powder, capsule, is characterized in that its preparation technology is:
Step one: according to aforementioned proportion, mixes stirring 30 minutes by polyhexamethylene guanidine and corn starch, obtains mixture A;
Step 2: according to aforementioned proportion, mixes stirring 30 minutes by mixture A and anhydrous glucose, obtains mixture B;
Step 3: according to aforementioned proportion, mixes stirring 30 minutes by mixture B and lactose, obtains polyhexamethylene guanidine drug powder;
Step 4: by polyhexamethylene guanidine drug powder according in a certain amount of incapsulating, just obtain polyhexamethylene guanidine medicament capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510428434.6A CN105030684A (en) | 2015-07-20 | 2015-07-20 | Formula for polyhexamethylene guanidine medicine powder and capsules and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510428434.6A CN105030684A (en) | 2015-07-20 | 2015-07-20 | Formula for polyhexamethylene guanidine medicine powder and capsules and method for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105030684A true CN105030684A (en) | 2015-11-11 |
Family
ID=54438057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510428434.6A Pending CN105030684A (en) | 2015-07-20 | 2015-07-20 | Formula for polyhexamethylene guanidine medicine powder and capsules and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030684A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853369A (en) * | 2016-06-03 | 2016-08-17 | 卫国刚 | Polyhexamethylene guanidine drug for treating livestock, poultry and fish digestive system infection and preparing method thereof |
| WO2017185596A1 (en) * | 2016-04-25 | 2017-11-02 | 卫国刚 | Polyhexamethylene guanidine medicament for treating gastrointestinal diseases, method for preparing same and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705536A (en) * | 2014-01-03 | 2014-04-09 | 卫望奎 | Pharmaceutical formula of polyhexamethylene guanidine hydrochloride (PHMG) and preparation method |
-
2015
- 2015-07-20 CN CN201510428434.6A patent/CN105030684A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705536A (en) * | 2014-01-03 | 2014-04-09 | 卫望奎 | Pharmaceutical formula of polyhexamethylene guanidine hydrochloride (PHMG) and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 韩瑞亭: "《药物制剂技术》", 31 March 2009 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017185596A1 (en) * | 2016-04-25 | 2017-11-02 | 卫国刚 | Polyhexamethylene guanidine medicament for treating gastrointestinal diseases, method for preparing same and use thereof |
| CN105853369A (en) * | 2016-06-03 | 2016-08-17 | 卫国刚 | Polyhexamethylene guanidine drug for treating livestock, poultry and fish digestive system infection and preparing method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pavan | Acute kidney injury following Paraquat poisoning in India | |
| CN105125574A (en) | Formula and preparation process of polyhexamethylene guanidine drug powder for beasts and birds | |
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN101934070A (en) | Veterinary antibacterial drug composition containing lysozyme and oligosaccharide and application thereof | |
| CN102000105B (en) | Compound timicosin oral liquid and preparation method thereof | |
| CN111920753A (en) | Preparation for resisting helicobacter pylori and relieving gingivitis and application thereof | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN105030684A (en) | Formula for polyhexamethylene guanidine medicine powder and capsules and method for preparing same | |
| WO2007117102A1 (en) | Complex antibiotic composition for bovine mastitis | |
| CN108404111A (en) | One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component | |
| CN104839458A (en) | Polyhexamethylene guanidine medicated feed additive | |
| CN101804094B (en) | Medicament for killing sperms in vitro | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN102614294A (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| WO2017185596A1 (en) | Polyhexamethylene guanidine medicament for treating gastrointestinal diseases, method for preparing same and use thereof | |
| CN103845284A (en) | Neomycin sulfate solution and preparation method thereof | |
| CN101991587A (en) | Compound sulfadiazine injection and preparation method thereof | |
| CN105343122A (en) | Propanoic acid polyhexamethylene guanidine livestock, poultry and fish pharmaceutical preparation | |
| CN105213420A (en) | The pharmaceutical preparation of polyhexamethylene guanidine propionate intestines and stomach | |
| CN101966201A (en) | Compound norfloxacin nicotinic soluble powder and preparation method thereof | |
| CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
| CN112741826A (en) | New application of niclosamide | |
| WO2013081284A1 (en) | Complex antibacterial composition for animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151111 |
|
| RJ01 | Rejection of invention patent application after publication |